长春高新：控股子公司两款药品新纳入国家医保目录

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has received inclusion of its self-developed JinSaiZeng (growth hormone injection) and the co-introduced Meishiya (medroxyprogesterone acetate oral suspension) into the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] Group 1 - The inclusion of these drugs reflects national recognition and is expected to facilitate market promotion and enhance sales scale [1] - The medical insurance payment standards will be effective from January 1, 2026, to December 31, 2027 [1] - The impact on the company's performance from this inclusion is currently difficult to estimate [1] Group 2 - The new drug list will be implemented starting January 1, 2026, with reimbursement details to be determined by government announcements [1]